Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pseudomyxoma Peritonei 1Blood Coagulation Disorders 1Afibrinogenemia 1

Interventions

Specimen Handling 631pembrolizumab 610Magnetic Resonance Spectroscopy 553Carboplatin 450Cisplatin 398Cyclophosphamide 397Biopsy 375Nivolumab 326Paclitaxel 324Gemcitabine 317Radiotherapy 286Bevacizumab 244Dexamethasone 222fludarabine 215Docetaxel 199durvalumab 195venetoclax 188Oxaliplatin 187atezolizumab 184Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 169Radiation 167Doxorubicin 166Radiosurgery 159Ipilimumab 147Etoposide 142Leucovorin 141Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × cryoprecipitate coagulum × 90 days × Clear all
NCT06617897 2026-03-11

Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

CSL Behring

Phase 3 Recruiting
90 enrolled

Afibrinogenemia, Blood Coagulation Disorders, Pseudomyxoma Peritonei

Data powered by HemOnc (CC BY 4.0) Colophon âš¡